PBMs Oppose Formulary Levers, Favor Automatic Switch To All Biosimilars

As Senate Finance Committee lawmakers continue talks on a measure to boost biosimilars using formulary levers, the pharmacy benefit manager industry strongly opposes the idea and is lobbying Congress to instead allow brand biologics to be automatically switched to biosimilars, including those deemed non-interchangeable by FDA. The PBM lobby praises CMS for recently proposing the idea , and backs legislation pending in the Senate that would cement the policy. The Pharmaceutical Care Management Association hailed The Biosimilar Red Tape Elimination...